Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

about

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

P2860

Q55101112-414C7820-7015-4DA9-9A99-EF54EB2154ED

P2860

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Item

http://www.wikidata.org/entity/Q38965214

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Continuous dosing versus inter ...... o phase 3 trials in psoriasis.

@en

type

Item

label

Continuous dosing versus inter ...... o phase 3 trials in psoriasis.

@en

prefLabel

Continuous dosing versus inter ...... o phase 3 trials in psoriasis.

@en

P1476

Continuous dosing versus inter ...... wo phase 3 trials in psoriasis

@en

P2093

A Blauvelt

http://www.w3.org/2001/XMLSchema#string

D Shrom

http://www.w3.org/2001/XMLSchema#string

G Yosipovitch

http://www.w3.org/2001/XMLSchema#string

H Sofen

http://www.w3.org/2001/XMLSchema#string

K B Gordon

http://www.w3.org/2001/XMLSchema#string

K See

http://www.w3.org/2001/XMLSchema#string

L Mallbris

http://www.w3.org/2001/XMLSchema#string

M Augustin

http://www.w3.org/2001/XMLSchema#string

M Ohtsuki

http://www.w3.org/2001/XMLSchema#string

N Katoh

http://www.w3.org/2001/XMLSchema#string

P2860

Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy

Severe psoriasis--oral therapy with a new retinoid.

Duration of remission of biologic agents for chronic plaque psoriasis.

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.

Continuous versus intermittent therapy for moderate-to-severe psoriasis.

The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

P304

1004-1013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDV.14163

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kim A. Papp

P577

2017-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28190255

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

5485049

http://www.w3.org/2001/XMLSchema#string

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

about

P2860

P2860

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932